BioLineRx Ltd. (BLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLRX Stock Price Chart Interactive Chart >
BLRX Price/Volume Stats
|Current price||$0.63||52-week high||$1.98|
|Prev. close||$0.63||52-week low||$0.55|
|Day high||$0.63||Avg. volume||269,835|
|50-day MA||$0.66||Dividend yield||N/A|
|200-day MA||$1.11||Market Cap||38.76M|
BioLineRx Ltd. (BLRX) Company Bio
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company was founded in 2003 and is based in Modiin, Israel.
Most Popular Stories View All
BLRX Latest News Stream
|Loading, please wait...|
BLRX Latest Social Stream
View Full BLRX Social Stream
Latest BLRX News From Around the Web
Below are the latest news stories about BIOLINERX LTD that investors may wish to consider to help them evaluate BLRX as an investment opportunity.
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions. Her appointment is effective today, January 4, 2023.
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!
BioLineRx Ltd (NASDAQ: BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors. The study met its primary endpoint of AGI-134's safety and tolerability. In this first-in-human trial, 38 patients were treated with AGI-134. Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached, and the recommended dose for
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced results from the Phase 1/2a study of intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors.
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Third Quarter 2022 Operational and Financial Results On November 15, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 3Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update
BLRX Price Returns